This question has been answered by the relevant Government Department.
Lord Mendelsohn to ask Her Majesty's Government what assessment they have made of whether their strategy to protect immuno-compromised individuals is over reliant on (1) second line treatments using Sotrovimab, and (2) fourth line treatments using Molnupiravir. HL728
Legend for business item text
† Item that is new or altered.
[I] Indicates that the member concerned has a relevant registered interest.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.
Member's Registered Interests
There are no interests to show.